

Contents

1	Triage Optimisation in Patients with Symptoms Suspicious of Colorectal Cancer	1
	Ian Bissett and Kai Sheng Saw	
1.1	Introduction	2
1.2	Symptoms Suggestive of Colorectal Cancer	3
1.3	Current Challenges of Diagnosing Colorectal Cancer Amongst Symptomatic Patients	4
1.3.1	Risks of Invasive Investigations	4
1.3.2	Low Patient Acceptability	5
1.3.3	Excessive Investigation and Low Value Healthcare	5
1.3.4	Opportunity Costs Associated with Reliance on Symptoms for Risk Assessment	6
1.3.5	Supply and Demand Imbalance	7
1.4	The Need for Triage and Defining Optimum	8
1.5	An Overview of Current Approaches to Triage	10
1.6	The Faecal Immunochemical Test (FIT)	15
1.7	Implementing FIT—A Proposed Triage Approach	22
1.8	Further Questions	25
1.9	Conclusions	27
	References	28
2	Total Neoadjuvant Therapy (TNT) in Rectal Cancer; Where Now, Where Next?	35
	S. Bedrikovetski and T. Sammour	
2.1	Introduction	36
2.2	Where Are We Now?	37
2.2.1	Induction Chemotherapy	37
2.2.2	Consolidation Chemotherapy	40
2.2.3	Induction Versus Consolidation Chemotherapy Sequencing	44
2.2.4	Total Neoadjuvant Therapy Combined with Immunotherapy or Biologics	46

2.3	Where Next?	48
2.3.1	Personalized Total Neoadjuvant Therapy Sequencing	48
2.3.2	Optimising Chemotherapy Regimen	49
2.3.3	Neoadjuvant Chemotherapy or Immunotherapy with Selective Omission of Radiotherapy	50
2.3.4	Pushing the Boundaries of Nonoperative Management	51
2.3.5	Quality of Life Implications	52
2.4	Conclusion	53
	References	54
3	Quality of Life and Survivorship in Extended Pelvic Resection for Advanced and Recurrent Malignancy	61
	Deena Harji and Claire Taylor	
3.1	Introduction	62
3.2	Quality of Life Outcomes	62
3.2.1	Physical Function	63
3.2.2	Psychological Function	63
3.2.3	Role Function	64
3.2.4	Sexual Function	64
3.2.5	Body Image	65
3.2.6	Occupational and Financial Impact	65
3.2.7	Global QoL and General Health	66
3.2.8	QoL Assessment	66
3.3	Cancer Survivorship	67
3.4	After-Care Models	68
3.5	Symptom Management	69
3.6	Pain	69
3.7	Stoma Care	70
3.8	Empty Pelvis Syndrome	70
3.9	Fatigue	71
3.10	Mobility	71
3.11	Conclusion	72
	References	72
4	Lynch Syndrome	77
	Penelope Edwards and Kevin J. Monahan	
4.1	Introduction	79
4.2	History and Epidemiology	83
4.2.1	History of Lynch Syndrome	83
4.2.2	Epidemiology	84
4.2.3	Gene-Specific Cancer Risk	85
4.3	Diagnosis of Lynch Syndrome: MMR Testing	89
4.4	Biology of Lynch Syndrome; Molecular Pathways	94

4.5	Pathways to Carcinogenesis; Adenomatous and Non-adenomatous	95
4.5.1	Cancer from pMMR Adenoma	96
4.5.2	Cancer from dMMR Precursor, Adenoma	97
4.5.3	Cancer from dMMR Precursor, 'Non-Polypous' Route	97
4.6	Role of Surveillance Colonoscopy	98
4.6.1	Quality Factors in Colonoscopy	98
4.6.2	Advanced Imaging Techniques	99
4.6.3	Variables in Sidedness Affecting Risk Reduction	100
4.6.4	Frequency of Colonoscopy	100
4.6.5	Barriers to Colonoscopy Adherence	101
4.7	Colorectal Surgical Management of Lynch Syndrome	103
4.7.1	Extensive or Segmental Resection?	103
4.8	Prophylactic Surgery and Screening in Gynaecological Cancer	103
4.8.1	Gene-Specific Risk and Risk Reduction Surgery	103
4.8.2	Considerations Post-surgery	104
4.8.3	Pathological Features of Gynaecologic Cancers in Lynch Syndrome	105
4.8.4	Gynaecological Surveillance	105
4.9	Role of Screening in Other Cancers	105
4.9.1	Upper Gastrointestinal (GI) Cancer Screening	105
4.9.2	Urological Cancer Screening; Urothelial and Prostate	107
4.9.3	Pancreatic Screening	107
4.9.4	Diagnostic Testing Strategies Pan-Cancer Approach	108
4.10	Lifestyle and Chemoprevention	108
4.10.1	Environmental/Lifestyle Modifiers in Lynch Syndrome	108
4.10.2	Pharmacologic Agents	110
4.10.3	Endometrial Risk Reducing Agents	113
4.11	Oncological Management: Radical and Advanced	114
4.11.1	CRC	114
4.11.2	Immunotherapy; the Basics	114
4.11.3	Clinical Trial Data for Use of Immunotherapy in CRC: Sporadic and Germline	114
4.11.4	Targeted Treatments in LS Associated Gynaecological Cancers	118
4.11.5	Toxicities Related to Immune Checkpoint Blockade	118
4.11.6	Vaccine Based Therapies	118

4.12	Future Directions	119
4.13	Conclusion	121
	References	121
5	Neoadjuvant Therapy in Colon Cancer	133
	Geerard L. Beets	
5.1	Introduction	134
5.2	Rationale for Neoadjuvant Chemotherapy	135
5.3	Evidence on Neoadjuvant Chemotherapy	136
5.4	Current Status and Remaining Questions on Neoadjuvant Chemotherapy	138
5.5	Circulating Tumour DNA and Adjuvant Therapy	139
5.6	Immunotherapy—Immune Checkpoint Inhibition (ICI)	140
	5.6.1 Deficient Mismatch Repair (dMMR) and Microsatellite Instability (MSI)	140
	5.6.2 Neoadjuvant Immunotherapy in Colorectal Cancer	141
5.7	Conclusions	143
	References	144
6	Appendix Neoplasms	147
	Paul A. Sutton and Sarah T. O'Dwyer	
6.1	The Normal Appendix	148
	6.1.1 Histopathology	149
	6.1.2 Function	149
	6.1.3 Appearances on Imaging	150
6.2	Pathology of Appendix Tumours	150
	6.2.1 Neuroendocrine Neoplasms	151
	6.2.2 Appendiceal Mucinous Neoplasms	151
	6.2.3 Appendix Adenocarcinoma	153
	6.2.4 Goblet Cell Adenocarcinoma	154
6.3	Appendiceal Neuroendocrine Tumours	155
	6.3.1 Clinical Presentation	155
	6.3.2 Investigations	155
	6.3.3 Management	155
	6.3.4 Surveillance and Outcomes	157
6.4	Appendiceal Mucinous Neoplasms	157
	6.4.1 Clinical Presentation	157
	6.4.2 Pseudomyxoma Peritonei	158
	6.4.3 Investigations	159
	6.4.4 Surgical Management	160
	6.4.5 Multi-visceral Transplantation	163
	6.4.6 Systemic Anti-cancer Therapy (SACT)	163
	6.4.7 Surveillance and Outcomes	164
6.5	Appendix Adenocarcinoma	164
	6.5.1 Clinical Presentation	164
	6.5.2 Investigations	165

6.5.3	Surgical Management	165
6.5.4	Systemic Anti-cancer Therapy	165
6.5.5	Surveillance and Outcomes	166
6.6	Goblet Cell Adenocarcinoma	167
6.6.1	Clinical Presentation	167
6.6.2	Investigations	167
6.6.3	Surgical Management	168
6.6.4	Systemic Anti-Cancer Therapy (SACT)	168
6.6.5	Surveillance and Outcomes	169
6.7	Referring to Specialist Services	169
6.8	Current Research and Future Directions	170
6.9	Conclusion	171
	References	171
7	Patient Optimisation for Colorectal Surgery	179
	Carly N. Bisset and Susan J. Moug	
7.1	Introduction	180
7.2	Definition of Patient Optimisation: Preassessment and Prehabilitation	180
7.2.1	Pre-assessment	181
7.2.2	Prehabilitation	185
7.3	The Evidence for the Effectiveness of Prehabilitation	187
7.3.1	Patient Safety and Feasibility	187
7.3.2	Assessment of Prehabilitation	188
7.3.3	Trials, Systematic Reviews and Meta-Analyses	190
7.3.4	The Future of Prehabilitation	195
7.4	Conclusion	196
	References	197
8	Empty Pelvis Syndrome Complication Management Following Pelvic Exenteration	205
	Martha Quinn and Colin W. Steele	
8.1	Introduction	206
8.2	Empty Pelvis Syndrome	206
8.3	Prevention Strategies	207
8.3.1	Negative Pressure	208
8.3.2	Myocutaneous Flap Reconstruction	208
8.3.3	Mesh	209
8.3.4	Spacers	210
8.4	Summary	210
8.5	Complications and Management of Empty Pelvis Syndrome	211
8.5.1	Pelvic Collection	211
8.5.2	Haemorrhagic Complications	212
8.5.3	Wound Complications	213
8.5.4	Enteroperineal Fistula	215

8.5.5	Perineal Hernia	216
8.5.6	Conclusion	216
	References	217
9	Contemporary Management of the Open Abdomen	221
	Dominic Alexander James Slade	
9.1	Introduction	222
9.2	Indications for an Open Abdomen	222
9.2.1	Trauma and the Damage Control Laparotomy	224
9.2.2	Intra-Abdominal Hypertension and Abdominal Compartment Syndrome	226
9.2.3	Peritonitis and Intra-Abdominal Sepsis	229
9.2.4	Acute Mesenteric Ischaemia, Pancreatitis, and Burns Without Abdominal Trauma	233
9.3	Management of the Open Abdomen	234
9.3.1	Temporary Abdominal Closure Dressings	234
9.3.2	Static Temporary Abdominal Closure	235
9.3.3	Dynamic Temporary Abdominal Closure	237
9.3.4	Mixed Techniques	239
9.3.5	Vacuum-Assisted Wound Closure Using Mesh-Mediated Fascial Traction	240
9.3.6	Immediate Management of an Enteroatmospheric Fistula	243
9.4	Conclusion	244
	References	245
10	Anastomotic Techniques for Crohn's Surgery	251
	Antonino Spinelli and Elisa Paoluzzi Tomada	
10.1	Surgical Principles in Crohn's Disease	252
10.2	Restorative Surgery Techniques After Bowel Resection	255
10.3	Anastomotic Techniques After Ileocaecal Resection	255
10.3.1	Side-to-Side Ileocolonic Anastomosis	256
10.3.2	End-to-End Handsewn Ileocolonic Anastomosis	258
10.3.3	End-to-Side and Side-to-End Ileocolonic Anastomosis	259
10.3.4	Antimesenteric Hand-Sewn Functional End-to-End Anastomosis: Kono-S Anastomosis	260
10.3.5	Additional Anastomotic Techniques	263
10.4	Extracorporeal and Intracorporeal Anastomoses	264
10.5	Restorative Techniques After Colectomy, Proctocolectomy and Upper Gastrointestinal Surgery	265
10.5.1	Ileo-Rectal Anastomosis	265
10.5.2	Ileal Pouch-Anal Anastomosis and Coloanal Anastomosis	266
10.5.3	Surgical Management of the Upper Gastrointestinal Crohn's Disease Manifestations	266

10.6	Bowel-Sparing Surgery: Stricturoplasties	267
10.6.1	Heinecke-Mikulicz-Like Stricturoplasties	267
10.6.2	Intermediate Stricturoplasty Procedures	269
10.6.3	Enteroenterostomies	269
10.7	Complications in Crohn's Disease Surgery	271
10.8	Considerations on Disease Recurrence	272
10.9	Conclusions and Future Perspectives	274
	References	275
11	The Modern Management of Haemorrhoids	285
	Steven R. Brown	
11.1	Introduction	286
11.2	Pathogenesis and Classification	286
11.3	Conservative Management	288
11.3.1	Drug Therapy	288
11.3.2	Outpatient Treatment	288
11.3.3	'Walk in Walk Out' Therapy	290
11.4	Surgical Therapy	291
11.4.1	Haemorrhoidectomy	291
11.4.2	Procedure for Prolapsed Haemorrhoids	293
11.4.3	Doppler Guided Haemorrhoidal Artery Ligation	294
11.4.4	Laser	295
11.5	Special Situations	295
11.5.1	Thrombosed External Haemorrhoids	295
11.5.2	Perianal Haematoma	295
11.5.3	Haemorrhoids in Pregnancy	296
11.5.4	Anticoagulants	296
11.5.5	Immunocompromised	298
11.5.6	Haemorrhoids in Inflammatory Bowel Disease	298
11.6	Conclusion and an Evidence-Based Algorithm of Care	298
	References	299
12	Microbiome Manipulation in Coloproctology	303
	Nicholas R. Suss and Benjamin D. Shogan	
12.1	Introduction	304
12.2	Brief Overview of the Role of Gut Microbiome	304
12.3	"Healthy" Microbiota Composition	306
12.4	Manipulation of the Intestinal Microbiome and Its Role in the Pathogenesis of Gastrointestinal Disease	307
12.4.1	Inflammatory Bowel Disease	307
12.4.2	Development of Colorectal Cancer, Recurrence, and Metastasis	308
12.5	Clinical Manipulations of the Intestinal Microbiome to Target Disease	315
12.5.1	Restoring the Intestinal Microbiota Through Faecal Microbiota Transplantation	315

12.5.2	Inflammatory Bowel Disease	316
12.5.3	Bowel Preparation and Colon Cancer	317
12.5.4	Nutritional Prehabilitation and the Intestinal Microbiome	319
12.5.5	Impact of Nutritional Prehabilitation on the Intestinal Microbiota and Anastomotic Healing	320
12.6	Conclusion	321
	References	321
13	Restorative Proctocolectomy–Technical Challenges of the Ileal Pouch-Anal Procedure for Ulcerative Colitis and Familial Adenomatous Polyposis	327
	Peter Sagar	
13.1	Introduction	328
13.2	Principles of the Operation of IPAA	328
13.2.1	Choice of Pouch Design	329
13.2.2	The Ileal Pouch Anal Anastomosis	329
13.3	Post Operative Course and Potential Problems	332
13.3.1	Longer Term Problems	333
13.4	Crohn's Disease	335
13.5	Conclusion	335
	References	336
14	Contemporary Management of Fistula in Ano	337
	Philip Tozer and Lillian Reza	
14.1	Introduction	338
14.2	Clinical Presentation of Anal Fistula	339
14.3	Clinical Assessment of Anal Fistula	339
14.4	Imaging	340
14.5	Surgical Management	341
14.6	Conclusion	349
	References	350